此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients (PRESERVE)

2026年11月2日 更新者:Swedish Orphan Biovitrum

A 2-year, Single-arm, Multi-center Study to Explore the Efficacy and Safety of Pegcetacoplan in Preventing Disease Recurrence in Adolescent and Adult Kidney Transplant Recipients With C3 Glomerulopathy or Primary Immune-complex Membranoproliferative Glomerulonephritis

To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients

研究概览

详细说明

The PRESERVE study is a Phase 3b, multicenter, single-arm, open-label clinical trial designed to explore the efficacy and safety of pegcetacoplan in preventing or delaying the recurrence of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) following kidney transplantation. Recurrence of these diseases after transplantation is common and can lead to graft dysfunction and loss. Pegcetacoplan is a complement C3/C3b inhibitor that has demonstrated activity in patients with native kidney disease and recurrent disease after transplantation. The study aims to assess whether initiating pegcetacoplan at the time of kidney transplantation, before recurrence occurs, may delay the recurrence and support long-term graft outcomes. Participants will receive pegcetacoplan in addition to standard post-transplant care and will be followed to evaluate disease recurrence, kidney function, graft outcomes, safety, and tolerability.

研究类型

介入性

注册 (估计的)

30

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Alberta
      • Edmonton、Alberta、加拿大、T6G 2R7
        • University of Alberta - Faculty of Medicine & Dentistry
    • British Columbia
      • Vancouver、British Columbia、加拿大、V6Z 1Y6
        • St. Paul's Hospital
    • Ontario
      • London、Ontario、加拿大、N6A 5A5
        • London Health Sciences Centre (LHSC) - University Hospital
      • Toronto、Ontario、加拿大、M5G 2C4
        • Toronto General Hospital
    • Quebec
      • Montreal、Quebec、加拿大、H4A 3J1
        • McGill University Health Centre Research Institute
    • Pernambuco
      • Recife、Pernambuco、巴西、52010-010
        • Real Hospital Português
    • São Paulo
      • Botucatu、São Paulo、巴西、18618-970
        • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
      • São Paulo、São Paulo、巴西、05403-000
        • Hospital das Clinicas da Faculdade de Medicina da USP - HCFMUSP
    • Lower Saxony
      • Hanover、Lower Saxony、德国、30625
        • Medizinische Hochschule Hannover
    • North Rhine-Westphalia
      • Cologne、North Rhine-Westphalia、德国、50937
        • Universitaetsklinikum Koeln
      • Essen、North Rhine-Westphalia、德国、45147
        • Universitaetsklinikum Essen
    • Bari
      • Bari、Bari、意大利、70124
        • Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
    • Bergamo
      • Bergamo、Bergamo、意大利、24127
        • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
    • Roma
      • Roma、Roma、意大利、165
        • Ospedale Pediatrico Bambino Gesù
      • Roma、Roma、意大利、168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      • Riyadh、沙特阿拉伯、11211
        • King Faisal Specialist Hospital & Research Center
    • Bas Rhin
      • Strasbourg、Bas Rhin、法国、67091
        • CHU Strasbourg - Nouvel Hôpital Civil
    • Haute Garonne
      • Toulouse、Haute Garonne、法国、31059
        • Hopital Rangueil
    • Herault
      • Montpellier、Herault、法国、34000
        • Hopital Lapeyronie pt
    • Nord
      • Lille、Nord、法国、59037
        • Hopital Claude Huriez - CHU Lille
    • Paris
      • Paris、Paris、法国、75015
        • Hôpital Necker - Enfants Malades
    • Rhone
      • Lyon、Rhone、法国、69437
        • Hopital Edouard Herriot - CHU Lyon
      • Lausanne、瑞士、1011
        • Centre Hospitalier Universitaire Vaudois (CHUV)
      • Helsinki、芬兰、290
        • Helsinki University Central Hospital
    • Greater London
      • London、Greater London、英国、NW3 2QG
        • Royal Free Hospital
      • London、Greater London、英国、W12 0HS
        • Hammersmith Hospital
    • Greater Manchester
      • Manchester、Greater Manchester、英国、M13 9WL
        • Manchester Royal Infirmary
    • Tyne & Wear
      • Newcastle upon Tyne、Tyne & Wear、英国、NE7 7DN
        • Freeman Hospital
    • Barcelona
      • Barcelona、Barcelona、西班牙、8035
        • Hospital Universitari Vall d'Hebron - VHIR
    • La Coruña
      • A Coruña、La Coruña、西班牙、15006
        • Complejo Hospitalario Universitario A Coruña
    • Madrid
      • Madrid、Madrid、西班牙、28041
        • Hospital Universitario 12 de Octubre
    • Málaga
      • Málaga、Málaga、西班牙、29010
        • Hospital Regional Universitario de Malaga
    • Vizcaya
      • Barakaldo、Vizcaya、西班牙、48903
        • Hospital de Cruces

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

12年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Male or female patients with a diagnosis of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) who are planning to undergo kidney transplantation because of the disease.
  • Have a high risk of disease recurrence following kidney transplantation, based on either having a previous kidney allograft loss due to recurrence of C3G or primary IC-MPGN, or assessed as having a high risk by the investigator based on other clinical information.
  • Is fully vaccinated and up to date with their vaccinations against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B, in accordance with local guidelines, at the time of initiating pegcetacoplan.

Exclusion Criteria:

  • A known secondary cause for MPGN, including but not limited to monoclonal gammopathy of clinical significance, hepatitis B, hepatitis C, or autoimmune cryoglobulinemia.
  • History of invasive meningococcal disease.
  • History of malignancy, except for the following: cured basal or squamous cell skin cancer, curatively treated in situ disease, or currently malignancy-free and has been off-treatment for the malignancy for at least 5 years.
  • Hypersensitivity to pegcetacoplan or any of its excipients.
  • Known or suspected hereditary fructose intolerance.
  • Any other medical condition which, in the opinion of the Investigator, makes the participant unsuitable for inclusion.
  • Use of a complement inhibitor for the treatment of C3G or primary IC-MPGN within 1 month prior to the scheduled kidney transplantation surgery.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Pegcetacoplan

Pegcetacoplan, a complement C3/C3b inhibitor, administered according to the study protocol in kidney transplant recipients with high risk of recurring C3G or primary IC-MPGN

Dose amount based on age and weight Subcutaneous infusion twice-a-week. Adult participants aged 18 years or older at enrolment: 1080 mg

Adolescent participants aged 12 to 17 years at enrolment:

  • Weight ≥50 kg: 1080 mg
  • Weight 35 to <50 kg: 648 mg 1st dose, then 810 mg subsequently
  • Weight 30 to <35 kg: 540 mg for the first 2 doses, then 648 mg subsequently
其他名称:
  • APL-2
  • 阿斯帕韦利
  • 恩帕韦利

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Occurrence of Clinically Significant Recurrent Disease
大体时间:Within 2 years after kidney transplantation

Histological evidence of recurrent disease based on the histopathological assessment of the kidney biopsy

Within 2 years after kidney transplantation

次要结果测量

结果测量
措施说明
大体时间
Time to Onset of Clinically Significant Disease Recurrence
大体时间:Up to 2 years after kidney transplantation

To explore the impact of pegcetacoplan on time to clinically significant recurrence of C3G or primary IC-MPGN after kidney transplantation

Up to 2 years after kidney transplantation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 研究主任:Study Physician、Swedish Orphan Biovitrum AB (publ)

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年1月21日

初级完成 (估计的)

2031年1月17日

研究完成 (估计的)

2031年1月17日

研究注册日期

首次提交

2026年10月21日

首先提交符合 QC 标准的

2026年10月21日

首次发布 (实际的)

2026年10月27日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • Sobi.PEGCET-404
  • 2026-526392-39-00 (克蒂斯)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Qualified researchers may request access to patient level data and related study documents.

All requests are evaluated by a cross functional panel of experts within Sobi. Patient level data will be anonymized and study documents, if applicable, will be redacted to protect the privacy of trial participants.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅